Clinical Trial Search

Primary: Change in Anthropometric Measures Over Time — 1.97; -0.61; 1.39; 1.22 Z-score

Primary: Sensitivity of Imaging Modalities for the Detection of ACTH-secreting Non-pituitary Tumor in Patients — 96.3; 77.1; 66.7; 100 percentage of patients

Primary: Homeostasis Model Assessment Insulin Resistance (HOMA-IR) Index — 1.91; 0.84 units on a scale — p=0.001

Primary: FMD/Shear — 0.182; 0.206; 0.155; 0.219 %/s^-1

Primary: Insulin Secretion — 293.1; 234.7; 330.8; 300.4 uU/mL*10min

Primary: Insulin Sensitivity — -0.16; 2.62; -0.50; 1.83 micro International Units/mL — p=0.023

Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants

Primary: Percentage of Responders With Mean Urinary Free Cortisol (UFC) Within Normal Limits — 22.2 percentage of responders

Primary: Insulin Resistance — 3.8; 3.1 mg/kg/min

Primary: Maximum Oxygen Uptake at Baseline. — 29.0 mL/kg/min

Primary: Luteinizing Hormone Pulse Amplitude — 2.73; 1.12 IU/L

Primary: Change in Histology

Primary: Type of Hyperparathyroidism — 90; 276; 19; 61 Participants

Primary: Insulin Sensitivity — 3.06; 3.33 units on a scale

Primary: Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Secretion Rate — 3.13; 2.03; 4.66; 3.36 umol/min/L plasma — p=0.85

Primary: Insulin-mediated Glucose Disposal Rate at Levothyroxine Treatment Phase — 7.26 mg/kg/min

Primary: Mean Overnight Growth Hormone Levels — 0.85; 0.84 ng/mL — p=0.918

Primary: Change in Liver Fat — 0.03 Lipid/water ratio

Primary: Change in Weight — NA lbs

Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies

Primary: Peak Growth Hormone (GH) on the GH Stimulation Test — 40.1; 25.2 ng/ml — p=<0.05

Primary: Intelligence Quotient — 85.9; 104.3; 103.2 units on a scale

Primary: Hypertension (24h Blood Pressure, Central Blood Pressure, and Office BP) — 126.6; 131.1; 79.2; 78.9 mm Hg

Primary: Percentage With Growth Hormone (GH) Suppression to < 0.4 ng/ml — 0; 7; 8 Participants